Deepinder Goyal's Temple Startup Releases First Validation Study of Brain Flow Metric
Temple, a wearable technology startup founded by Zomato CEO Deepinder Goyal, has published its initial validation study showing its proprietary brain flow metric broadly tracked changes in cerebral blood flow.
Temple, the wearable technology startup founded by Zomato CEO Deepinder Goyal, has released its first validation study. Researchers found the company's proprietary brain flow metric broadly tracked changes in cerebral blood flow velocity, as measured by transcranial Doppler (TCD) ultrasound.
The study, published as a preprint and submitted for peer review, involved 23 healthy adults. It compared Temple's metric against TCD measurements during two activities designed to alter cerebral blood flow: stationary cycling and a postural change from standing to lying down. Data from 20 participants was analyzed under each protocol.
Temple's brain flow metric showed a median correlation of approximately 0.8 with middle cerebral artery blood-flow velocity across both activities. The findings suggest Temple's wearable can detect changes in brain blood flow that conventional heart-rate measurements might miss. For instance, during the postural test, cerebral blood-flow velocity increased when participants lay down, while heart rates declined. Temple's metric followed the direction of the Doppler reading despite the opposing heart rate change.
According to the publication, Temple's wearable can follow the direction and pattern of short-term changes in cerebral blood-flow velocity under controlled conditions. However, the study does not establish that the device can accurately measure absolute cerebral blood flow or diagnose medical conditions. Further research is needed to determine if Temple's brain flow metric specifically reflects brain activity and to establish potential clinical applications.
Temple raised approximately ₹493 crore (about $5.9 million) earlier this year from investors including Peak XV Partners and Steadview Capital. The company plans to open preorders and begin shipping devices by the end of 2026. Temple also recently acquired the UK-based Longevous clinic to bolster its clinical and scientific expertise ahead of the wearable's launch.